Summary
Improving the science of abuse assessment before a drug is marketed is a unified goal for the FDA and pharmaceutical industry. It is the hope that public health will be protected through placing appropriate controls, such as accurate labeling information and marketing practices, to reduce the likelihood that a drug will be abused after FDA approval.
Register to download
The Fundamentals of Human Abuse Potential (HAP) Studies: A 7-Point Checklist
You may also be interested in:
White Paper
Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes
Conducting clinical trials in rare diseases and advancing research pipelines requires a collaborative, multi-stakeholder approach. This process…
White Paper
Pharmacogenomics in Pain Management
Pharmacogenomics in Pain Management. In the US alone there are an estimated 100 million adults suffering from chronic pain. Pharmacogenomics and…
Poster
A Blueprint to Success: Onboarding a Medical Writer
Onboarding is the process of welcoming new employees into an organization and providing them with the tools, resources, and knowledge to become…